Portal de investigación
- Inicio
- Proyectos y Estudios
- ENSAYO CLÍNICO ALEATORIZADO, DOBLE CIEGO, DOBLE ENMASCARADO, DE GRUPOS PARALELOS CON CONTROL ACTIVO PARA EVALUAR LA EFICACIA ANTIVIRAL DE 400MG QD DE NEVIRAPINA LIBERACIÓN PROLONGADA (NEVIRAPINE ESTENDED RELEASE) EN COMPARACIÓN CON 200MG BID DE NEVIRAPIN A LIBERACIÓN INMEDIATA (NEVIRAPINE IMMEDIATE RELEASE) EN COMBINACIÓN CON TRUVADA® EN PACIENTES INFECTADOS POR VIH-1 QUE NO HAYAN RECIBIDO TRATAMIENTO ANTIRETROVIRAL PREVIO (NAÏVE). (VERVE).
ENSAYO CLÍNICO ALEATORIZADO, DOBLE CIEGO, DOBLE ENMASCARADO, DE GRUPOS PARALELOS CON CONTROL ACTIVO PARA EVALUAR LA EFICACIA ANTIVIRAL DE 400MG QD DE NEVIRAPINA LIBERACIÓN PROLONGADA (NEVIRAPINE ESTENDED RELEASE) EN COMPARACIÓN CON 200MG BID DE NEVIRAPIN A LIBERACIÓN INMEDIATA (NEVIRAPINE IMMEDIATE RELEASE) EN COMBINACIÓN CON TRUVADA® EN PACIENTES INFECTADOS POR VIH-1 QUE NO HAYAN RECIBIDO TRATAMIENTO ANTIRETROVIRAL PREVIO (NAÏVE). (VERVE).
Datos básicos
- Protocolo:
- 1100.1486
- EUDRACT:
- 2007-003654-29
- NCT:
- Centro:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
Santos JR; (...); Paredes R
Article. 10.1093/ofid/ofad542. 2023
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Tenorio CH; (...); Vallecillos CG
Article. 10.1016/j.ijantimicag.2024.107164. 2024
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).
Podzamczer D; (...); Moreno S
Article. 10.1093/ofid/ofab595. 2022
Differences in epidemiology and mortality between men and women with HIV infection in the CoRIS cohort from 2004 to 2014.
Muñoz Hornero C; (...); Pérez-Elías MJ
Article. 10.1016/j.eimce.2021.07.003. 2021
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Hidalgo-Tenorio, Carmen; (...); Garcia-Vallecillos, Coral
Article. 10.3390/v14030524. 2022
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Troya, Jesus; (...); Buzon, Luis
Article. 10.1097/MD.0000000000029252. 2022
Early Detection of Cancer and Precancerous Lesions in Persons with HIV through a Comprehensive Cancer Screening Protocol.
Gutierrez, Felix; (...); Masia, Mar
Article. 10.1093/cid/ciae359. 2024
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
Corona, Diana; (...); Rivero, Antonio
Article. 10.1016/j.ijantimicag.2023.107016. 2024
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
Santos JR; (...); Paredes R
Article. 10.3389/fcimb.2023.1187999. 2023
Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in treatment-naive and treatment-experienced patients
Suarez-Garcia, I.; (...); Jarrin, I.
Meeting Abstract. 2021
Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
Palacios, R.; (...); Santos, J.
Article. 10.1111/hiv.13489. 2023
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort
Teira, R; (...); Espinosa, N
Article. 10.1080/25787489.2021.1955197. 2021
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
Fanciulli C; (...); González Garcia J
Article. 10.1111/hiv.13229. 2022
Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.
Ruiz-Rodriguez P; (...); Coscolla M
Article. 10.1128/mBio.02315-21. 2021
Factors associated with late presentation for HIV care in adolescents in Spain
Epalza, Cristina; (...); Luisa Navarro, Maria
Article. 10.1111/hiv.13407. 2022
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018
Perez-Latorre, L; (...); Gonzalez-Garcia, J
Article. 10.2807/1560-7917.ES.2021.26.25.2000236. 2021
Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection.
Masiá M; (...); Martínez E
Article. 10.1186/s13063-021-05777-6. 2021
Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection (vol 22, 851, 2021)
Masia, M.; (...); Martinez, E.
Correction. 10.1186/s13063-023-07655-9. 2023
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir+Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.
Mussini, Cristina; (...); van Wyk, Jean
Article. 10.1007/s10461-024-04490-0. 2024
IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors.
Álvarez H; (...); Poveda E
Article. 10.3389/fimmu.2023.1257725. 2023
Knowledge, attitudes and practices in HIV-related chronic inflammation and cardiovascular risk in Spain
Serrano-Villar, Sergio; (...); de Isla, Leopoldo Perez
Article. 10.1016/j.eimc.2023.07.005. 2024
Knowledge, attitudes and practices in HIV-related chronic inflammation and cardiovascular risk in Spain.
Serrano-Villar, Sergio; (...); Perez de Isla, Leopoldo
Article. 10.1016/j.eimce.2023.07.009. 2023
Laboral Cranio-Facial Cellulitis with Perichondritis and External Otitis, A Case Report
Moreno, Eloy Sempere, Barcelo, Santos Ibanez, Alonso, Marta Montero
Editorial Material. 10.1016/j.eimc.2024.02.008. 2024
Laboral cranio-facial cellulitis with perichondritis and external otitis, a case report.
Sempere Moreno, Eloy, Ibanez Barcelo, Santos, Montero Alonso, Marta
Case Reports. 10.1016/j.eimce.2024.04.004. 2024
Long or complicated mpox in patients with uncontrolled HIV infection.
Corma-Gómez A; (...); Macías J
Article. 10.1002/jmv.29511. 2024
Long term follow-up in HCV infected patients with end stage chronic kidney disease after DAA therapy
Martinez-Camprecios, J; (...); Buti, M
Meeting Abstract. 2021
Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy.
Tarancon-Diez, Laura; (...); Muñoz-Fernández MÁ
Article. 10.1016/j.biopha.2023.114587. 2023
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
Martinez-Camprecios, Joan; (...); Buti, Maria
Article. 10.1016/j.gastrohep.2022.12.004. 2023
Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV( vol 106, pg 136, 2024)
Pelchen-Matthews, Annegret; (...); Wyatt, Christina M.
Correction. 10.1016/j.kint.2024.10.002. 2024
Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.
Pelchen-Matthews, Annegret; (...); Wyatt, Christina M.
Article. 10.1016/j.kint.2024.04.010. 2024
Monocyte Activation and Ageing Biomarkers in the Development of Cardiovascular Ischaemic Events or Diabetes in People with HIV.
Bernardino, Jose I.; (...); Rodes, Berta
Article. 10.3390/microorganisms11071818. 2023
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
Prevalence of people living with multidrug-resistant HIV and limited treatment options in Spain.
Llibre, Josep M; (...); Alcantara, Felipe Rodriguez
Article. 10.1111/hiv.13650. 2024
Prospective study for the early detection of lung carcinoma in patients with HIV infection (GESIDA study 8815).
Valencia ME; (...); González J
Article. 10.1016/j.eimce.2024.05.005. 2024
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV.
Teira, Ramon; (...); Berenguer, Juan
Article. 10.1371/journal.pone.0249515. 2021
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
Teira, Ramon; (...); Curran, Adria
Article. 10.1007/s40121-022-00630-y. 2022
Switching to bictegravir/ emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviralexperienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis
Podzamczer, D.; (...); Rivero, A.
Meeting Abstract. 2023
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer, Daniel; (...); Rivero, Antonio
Article. 10.1093/jac/dkad285. 2023
Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021.
Vinuela, Laura; (...); Garcia, Federico
Article. 10.1002/jmv.29287. 2023
Unplanned pregnancies and social and partner support during pregnancy in Spanish women living with HIV.
Ruiz-Alguero, Marta; (...); Jarrin, Inma
Article. 10.1111/hiv.13469. 2023